August 1, 2025
Annabelle Swain
This literature review looks at how psilocybin, the active compound in "magic mushrooms," can help people deal with death anxiety; the deep fear of dying or losing control that shows up in lots of mental health struggles. While traditional treatments like SSRIs and talk therapy work for some people, they don't always get to the root of the problem. Psilocybin works differently. It changes brain...
The International Journal of Neuropsychopharmacology
August 1, 2025
Andrew S. Gibbons, Paul Liknaitzky, Suresh Sundram
Abstract Background Early intervention and management of Generalised Anxiety Disorder (GAD) is essential to effectively reduce both symptom severity and the risk of developing other psychiatric disorders. However, current first-line treatments are only about 50% effective, with high rates of relapse and many adverse effects. Psychedelic medicines, such as psilocybin, have emerged as promising...
Current microbiology
July 15, 2025
Gokul Sudhakaran, Shreya Chakraborty, Ashok Kumar et al.
2 citations
Psilocybe species, commonly known as "magic mushrooms", are a group of hallucinogenic fungi known for their psychoactive compounds such as psilocybin, psilocin, baeocystin, and norbaeocystin. These species have been the focus of scientific study due to their potential therapeutic applications, despite their classification as controlled substances in many jurisdictions. This review aims to...
ACS Omega
July 10, 2025
Taynah Pereira Galdino, Lucas C Oliveira, Mateus A Luz et al.
5 citations
Innovative therapies, such as psilocybin-assisted psychotherapies, hold great promises for treating anxiety, depression, and various other mental health disorders, addressing some of the challenges faced by conventional psychiatric medicine. This study focuses on developing and validating an HPLC-DAD methodology for detecting psilocybin and psilocin in extracts from psychedelic mushrooms...
Arts Culture and Language
July 6, 2025
Yutong Song
Psilocybin, also known as “magic mushrooms,” is naturally found in psychedelic compound from different types of mushrooms. The utility of psilocybin for spiritual and therapeutic purposes has already go through several centuries. Scientific research on these compounds gained traction in the mid-20th century, the increasing interest in the possible therapeutic benefits of psilocybin has led to...
Brain and Behavior
July 1, 2025
Megan Calnan, Grace Blest‐hopley, Chris Busch et al.
4 citations
Abstract Background : Military veterans are at risk of various mental health conditions, with profound implications for post‐deployment quality of life. Current treatment options encounter high dropout rates and non‐responsiveness, and overlook the importance of community building in veterans’ holistic recovery. Preliminary research suggests psychedelics offer therapeutic benefits for...
Current Oncology
June 30, 2025
Haley D M Schuman, Chantal Savard, Raèf Mina et al.
9 citations
This systematic review and meta-analysis evaluates (1) the effectiveness of psychedelic-assisted therapy (PAT) using psilocybin and ketamine for psychosocial symptoms in adults with cancer, (2) contextualizes findings with non-randomized and exploratory studies of other psychedelics, and (3) examines the role of therapeutic frameworks in shaping outcomes. We searched PubMed, Cochrane Library,...
Cureus
June 24, 2025
Alfred Mathew, Roshan Dongre, Seo Hee Kim et al.
The coronavirus variant (causing the COVID-19 disease) that led to a pandemic sent global shockwaves, resulting in long-term effects on physical, mental, and social well-being and impacting both individuals and communities. With the pandemic's notable impact on mental health, one such potential treatment discussed in recent literature is psilocybin. Psilocybin is a naturally occurring prodrug...
British Journal of Pharmacology
June 15, 2025
Daniël Hoyer
9 citations
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N , N ‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g. ibogaine, ketamine and esketamine; and other atypicals e.g. dextromorphan/bupropion, esmethadone....
Therapeutic Advances in Psychopharmacology
June 8, 2025
Nadav Liam Modlin, Victoria Williamson, Carolina Maggio et al.
1 citation
Post-traumatic stress disorder (PTSD) and associated trauma and stressor-related disorders are common and debilitating, presenting significant treatment challenges due to their complex interplay of biological, cognitive, affective, somatic and social factors. Current treatments, while advancing and effective, yield limited efficacy for many individuals, underscoring the need for novel...